Lapinig, Anthony T.

HRN: 22 07 81  Sex: Male

Patient Encounter


AMS Audit List

Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
11/13/2022
CEFTRIAXONE 1G (VIAL)
11/13/2022
11/19/2022
IV
2g
Od
T/C Perforated Viscous Sec To GI Tb Vs Colonic New Growth
Waiting Final Action 
11/13/2022
METRONIDAZOLE 5MG/ML, 100ML (VIAL)
11/13/2022
11/19/2022
IV
500mg
Tid
T/c Perforated Perforated Viscous Sec To GI TN Vs Colonic New Growth
Waiting Final Action 
11/14/2022
PIPERACILLIN + TAZOBACTAM 4.5G (VLS)
11/14/2022
11/21/2022
IV
4.5
Q6h
Pelvic Abscess
Waiting Final Action 
11/14/2022
METRONIDAZOLE 5MG/ML, 100ML (VIAL)
11/14/2022
11/20/2022
IV
500mg
Q6h
Psoas Abscess
Waiting Final Action 

AMS Audit Form


Start Date: End Date:

Indication:

              

Type of Infection:

                             

           

Compliance to guidelines:



Initial appropriateness:



 If inappropriate:

           

Final appropriateness:



 If inappropriate:

              

Overall appropriateness: